Tobramycin

妥布霉素

Report date: 2026/05/02 20:00:18
NME

Base Information

Drug NameTobramycin
Drug Alias NameTobramisin妥新安欣Nebramycin Factor 6托霉素 +[19] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Action30S ribosomal subunit inhibitors
Targets30S ribosomal subunit
Therapy Area/IndicationsCritical IllnessCataractBlepharoptosis +[9] 
Global Approved IndicationsCystic FibrosisRespiratory Tract InfectionsBacterial Infections
Approved Indications in ChinaBacterial Infections
Original Approved Country/TerritoryN/A
Original Approved Date1974/01/01
Country/TerritoryCzechiaBelgiumUnited States +[18] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesViatrisNitto PharmaUniversity Of Calgary +[9] 
Inactive CompaniesShenZhen Taitai Pharmaceutical Industry Co LtdGuangzhou Institute Of Respiratory HealthBausch & Lomb Incorporated +[8] 
Active IndicationsCritical IllnessBronchopulmonary DysplasiaBronchiectasis +[6] 
Inactive IndicationsCataractBlepharoptosisPseudomonas Infections

Other Information

ATC CodeJ01GB01S01AA12
Related LinksWikipediaDrugBankKEGG